Protein–protein interactions (PPI) were once considered 'undruggable', but clinical
successes, driven by advanced methods in drug discovery, have challenged that notion …

The PROteolysis TArgeting C himeric (PROTAC) concept has provided an opportunity for
the discovery and development of a completely new type of therapy involving induction of …

Proteins of the bromodomain and extra-terminal (BET) family are epigenetics “readers” and
promising therapeutic targets for cancer and other human diseases. We describe herein a …

Breast cancer is susceptible to Candida infections, and candidiasis has an enhancing effect
on the progression and metastasis of tumor. Breast cancer and concurrent candidiasis …

Neuropathic pain (NP) is an intolerable pain syndrome that arises from continuous
inflammation and excitability after nerve injury. Only a few NP therapeutics are currently …

The relay delivery strategy is a two-step targeting approach based on two distinct modules in
which the first step with an initiator is to artificially create a target/environment which can be …

The functions of the bromodomain and extra terminal (BET) family of proteins have been
proved to be involved in various diseases, particularly the acute myeloid leukemia (AML). In …

Recently, selective inhibition of BET BD2 is emerging as a promising strategy for drug
discovery. Despite significant progress in this area, systematic studies of selective BET BD2 …

HDAC inhibitors and BRD4 inhibitors were considered to be potent anti-cancer agents.
Recent studies have demonstrated that HDAC and BRD4 participate in the regulation of …

Targeted degradation of BET family proteins BRD2/3/4 or only BRD4 with PROTAC
molecules has been a promising strategy for the treatment of human cancer. Meanwhile …